Stéphane Bancel, Moderna CEO (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)
November 7, 2024 06:30 AM ESTUpdated 06:48 AM
People
Pharma

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Max Bayer

Pharma Reporter

Mod­er­na re­vealed the con­se­quences of its late start in the mar­ket for RSV vac­cines, re­port­ing just $10 mil­lion in third-quar­ter sales from the new shot …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times